Somavert (Pegvisomant) - Summary

SOMAVERT SUMMARY

SOMAVERT contains pegvisomant for injection, an analog of human growth hormone (GH) that has been structurally altered to act as a GH receptor antagonist.

SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum IGF-I levels.

SOMAVERT NEWS HIGHLIGHTS

Published Studies Related to Somavert (Pegvisomant)

Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. [2006.08]

Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. [2005.10]

High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization. [2004.02]

A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. [2002.04]

Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. [2002.04]

more>>

Clinical Trials Related to Somavert (Pegvisomant)

Acute Application of Pegvisomant and Octreotide in Acromegaly [Completed]

Pegvisomant And Sandostatin LAR Combination Study [Completed]

Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients [Completed]

Canadian Pegvisomant Compassionate Study In Acromegalic Patients [Completed]

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients [Active, not recruiting]

more>>